ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Early C-reactive Protein Kinetics Predict Response to Immune Checkpoint Blockade in Unresectable Hepatocellular Carcinoma

Qin, Qiuying; Kou, Xiaoxuan; Zheng, Yuanyuan; Zhou, Fei; Zhang, Xiaoyong*; Liu, Hongyan*南方医科大学
Journal of Hepatocellular Carcinoma2023DOI: 10.2147/JHC.S432054
12阅读
引用收藏
分享

摘要

Purpose: In recent years, a new therapeutic approach, known as immune checkpoint blockade (ICB), has been proposed as approach to improve outcomes in patients with intermediate stage (Barcelona Clinic Liver Cancer, BCLC B) or advanced stage (BCLC C) hepatocellular carcinoma (HCC). Unfortunately, only a select patients can benefit from ICB. Hence, biomarkers that can predict the success and survival of treatment are still necessary.Patients and Methods: Between 2018 to 2021, 132 patients received ICB treatment for intermediate or advanced stage HCC. Based on the early kinetics of C-reactive protein (CRP), the patients were classified into three groups. The study endpoints were progression free survival (PFS) and overall survival (OS).Results: Our findings support the predictive power of early CRP kinetics in determining immunotherapy response for intermediate or advanced HCC. Objective response rates (ORR) were found in 41.2% of CRP flare-responders, 13.3% of CRP responders, and 3.5% of CRP non-responders (p<0.001). Disease control rates (DCR) in the three groups were substantially different (p<0.001). The improved PFS and OS were strongly correlated with the early kinetics of CRP. Compared to CRP non-responders, CRP responders, especially CRP flare-responders, had significantly longer PFS (median PFS: CRP flare-responders: 11.6 months vs CRP responders: 5.2 months vs CRP non-responders: 2.3 months, p<0.001).Conclusion: The CRP flare response robustly predicts the immunotherapy response and outcomes in patients with HCC. Early CRP kinetics may be an inexpensive, easily implemented and non-invasive biomarker to anticipate response to ICB therapy in intermediate or advanced HCC, with the potential to optimize treatment monitoring.

学科与关键词

关键词
hepatocellular carcinomaC-reactive protein kineticsCRP flare responseimmune checkpoint blockadebiomarkerimmunotherapy
相关
加载中…
  • Hepatocellular carcinoma immune prognosis score predicts the clinical outcomes of hepatocellular carcinoma patients receiving immune checkpoint inhibitors
    Zhang, Rujia; Zhao, Haoran; Wang, Peng; Guo, Zuoming; Liu, Chunxun; Qu, Zhaowei*BMC CANCER, 2023, 23(1): 1181.
  • Prognostic value of nutritional and inflammatory markers in patients with hepatocellular carcinoma who receive immune checkpoint inhibitors
    Liu, Chunxun; Zhao, Haoran; Zhang, Rujia; Guo, Zuoming; Wang, Peng; Qu, Zhaowei*Oncology Letters, 2023, 26(4): 437.
  • Predictive Value of the Hepatic Immune Predictive Index for Patients with Primary Liver Cancer Treated with Immune Checkpoint Inhibitors
    Hong, Chang; Dong, Han-Zhi; Li, Rui-Ning; Zhu, Hong-Bo; Li, Qi-Mei; Cui, Hao; Hu, Cheng-Yi; Huang, Chao-Yi; Peng, Jie; Liu, Li*; Zou, Xue-Jing*; Xiao, Lu-Shan*DIGESTIVE DISEASES, 2023, 41(3): 422-430.被引 3
查看全部 →

发表信息

论文状态
公开发表
期刊
Journal of Hepatocellular Carcinoma
发表日期
2023
卷期
第 10 卷
页码
2009-2019
DOI
10.2147/JHC.S432054
成果收录
SCIE
资助标注
National Natural Science Foundation of China [81970539, 82172257]; Health Care Major Project of Guangzhou [202206080001]

作者

  • Q

    Qin, Qiuying (第一作者)

    southern med univ

  • K

    Kou, Xiaoxuan

    southern med univ

查看全部 6 位作者收起作者
  • Z

    Zheng, Yuanyuan

    southern med univ

  • Z

    Zhou, Fei

    southern med univ

  • Z

    Zhang, Xiaoyong (通讯)

    southern med univ

  • L

    Liu, Hongyan (通讯)

    southern med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417